GRTS Stock Overview
A clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gritstone bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.53 |
| 52 Week High | US$3.33 |
| 52 Week Low | US$0.45 |
| Beta | 0.50 |
| 11 Month Change | -25.69% |
| 3 Month Change | -32.68% |
| 1 Year Change | -68.82% |
| 33 Year Change | -92.86% |
| 5 Year Change | -94.73% |
| Change since IPO | -96.28% |
Recent News & Updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation
Jun 11
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Apr 07Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%
Aug 14Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Sep 26Gritstone reaches six-month high on publication of data for cancer vaccine
Aug 16Gritstone bio announces $80M credit facility
Jul 21Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?
Jul 07Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Jul 05Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Jun 14Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates
Mar 17We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate
Mar 05Gritstone: Why The Stock Fell On Positive Data
Jan 18Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business
Nov 23Gritstone Poised To Dominate mRNA Market
Nov 08Shareholder Returns
| GRTS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | 2.7% | 4.0% |
| 1Y | -68.8% | 15.4% | 24.9% |
Return vs Industry: GRTS underperformed the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: GRTS underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| GRTS volatility | |
|---|---|
| GRTS Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GRTS's share price has been volatile over the past 3 months.
Volatility Over Time: GRTS's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 231 | Andrew Allen | gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
| GRTS fundamental statistics | |
|---|---|
| Market cap | US$61.42m |
| Earnings (TTM) | -US$133.03m |
| Revenue (TTM) | US$14.61m |
4.3x
P/S Ratio-0.5x
P/E RatioIs GRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRTS income statement (TTM) | |
|---|---|
| Revenue | US$14.61m |
| Cost of Revenue | US$119.55m |
| Gross Profit | -US$104.94m |
| Other Expenses | US$28.09m |
| Earnings | -US$133.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | -718.30% |
| Net Profit Margin | -910.56% |
| Debt/Equity Ratio | 182.5% |
How did GRTS perform over the long term?
See historical performance and comparison